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Abstract
Background/Aims—Drug-induced and indeterminate Acute Liver Failure (ALF) might be due
to an autoimmune-like hepatitis that is responsive to corticosteroid therapy. The aim of this study
was to evaluate whether corticosteroids improve survival in fulminant autoimmune hepatitis, druginduced or indeterminate ALF, and whether this benefit varies according to the severity of illness.
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Methods—We conducted a retrospective analysis of autoimmune, indeterminate and druginduced ALF patients in the Acute Liver Failure Study Group from 1998-2007. The primary
endpoints were overall and spontaneous survival (SS, survival without transplant).
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Results—361 ALF patients were studied, 66 with autoimmune (25 steroids, 41 no steroids), 164
with indeterminate (21 steroids, 143 no steroids), and 131 with drug-induced (16 steroids, 115 no
steroids) ALF. Steroid use was not associated with improved overall survival (61% vs. 66%,
p=0.41), nor with improved survival in any diagnosis category. Steroid use was associated with
diminished survival in certain subgroups of patients, including those with the highest quartile of
MELD (MELD > 40, survival 30% vs. 57%, p=0.03). In multivariable analysis controlling for
steroid use and diagnosis, age (OR 1.37 per decade), coma grade (OR 2.02 grade 2, 2.65 grade 3,
5.29 grade 4), MELD (OR 1.07) and pH<7.4 (OR 3.09) were significantly associated with
mortality. Though steroid use was associated with a marginal benefit in SS overall (35% v. 23%,
p=0.047), this benefit did not persistent in multivariable analysis; mechanical ventilation (OR
0.24), MELD (OR 0.93), and ALT (1.02) were the only significant predictors of SS.
Conclusions—Corticosteroids did not improve overall survival or SS in drug-induced,
indeterminate or autoimmune ALF and were associated with lower survival in patients with the
highest MELD scores.
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Introduction
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Acute liver failure (ALF) is a heterogeneous syndrome resulting in rapid deterioration of
liver function with subsequent coagulopathy and encephalopathy in a previously healthy
individual.1 Drug-induced (DI)-ALF is the most common etiology, the majority of which is
due to the intrinsic hepatotoxin, acetaminophen,2 and the remainder due to idiosyncratic
drug reactions, presumably immune-mediated liver injury due to the metabolic generation of
a neo-antigen3. Approximately 4% of ALF cases are believed to be secondary to
autoimmune acute liver failure (AI-ALF), although diagnostic criteria have not been well
developed, and are primarily based upon criteria for patients with classical autoimmune
hepatitis (AIH). The etiology of another 17% of ALF cases remains indeterminate after
extensive evaluation. Recently, we have suggested that many patients with ALF of
indeterminate etiology have AI-ALF, and have proposed histological features suggestive of
an autoimmune pathogenesis.4
The prognosis of patients with non-acetaminophen-induced ALF remains very poor, with
transplant-free or spontaneous survival (SS) rates of only 44%. Patients with idiosyncratic
drug-induced, indeterminate, and AI-ALF have a particularly dismal SS rate of < 25%.2
There are no etiology-specific treatments that have improved the prognosis of nonacetaminophen ALF, and the trend toward increased SS in the last 30 years can be primarily
attributed to improved critical care management.
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The administration of glucocorticoids in patients with potentially immune-mediated ALF
remains controversial after early studies suggested no benefit or even an adverse effect.5-7
AI-ALF may theoretically respond to corticosteroids based upon their efficacy in patients
who present with classical AIH and a few case reports of AI-ALF, although the largest series
published to date concluded that corticosteroids might be harmful and may increase the risk
of infection around the time of liver transplantation. 1,8,9 The use of corticosteroids has also
been proposed as a potential treatment for idiosyncratic DI-ALF based upon a presumed
immune-mediated pathogenesis6 and the fact that the innate immune system plays a key role
in the development of ALF in humans and in animal models.10-12 In specific idiosyncratic
drug reactions from HMG-CoA reductase inhibitors--“statins”, antibiotics, and non-steroidal
anti-inflammatory drugs, glucocorticoid administration has ameliorated the liver injury. 8-13
While it remains unclear whether these cases of DI-ALF induce bona fide AI-ALF or only
mimic it, the frequent appearance of autoantibodies supports the former possibility. Based
upon our previous observations that patients with indeterminate ALF have histological
features of autoimmunity on liver biopsy, we also postulated that corticosteroids might also
benefit this sub-population. The administration of corticosteroids may therefore represent an
opportunity to reverse severe immune-mediated injury and obviate the need for liver
transplantation.
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Consequently, the aim of the present study was to evaluate the efficacy of corticosteroids in
improving overall survival and SS in 3 groups of ALF with a potentially autoimmunemediated pathogenesis: those with AI-ALF, indeterminate ALF, and DI-ALF. Considering
the clinical heterogeneity of patients with the ALF syndrome, subgroup analyses were
undertaken to determine whether the possible benefit of corticosteroids were associated with
the severity of the clinical syndrome at time of presentation.

Materials and Methods
Patients and Study Design

Author Manuscript

We conducted a retrospective analysis of all patients enrolled in the Acute Liver Failure
Study Group (ALFSG) Registry between 1998-2007 who were deemed to have either AIALF, indeterminate ALF, or DI-ALF by the site Principal Investigator (PI). The ALFSG
study cohort and its outcomes have been previously described. 16 A total of 361 consecutive
patients were enrolled with ALF. Inclusion criteria included coagulopathy (international
normalized ratio of prothrombin time [INR] ≥1.5) and any degree of hepatic encephalopathy.
After informed consent was obtained from next of kin, detailed prospective clinical and
laboratory data were collected in an anonymous fashion on admission to the study and for 7
consecutive days until Day 21, or the time of death or liver transplantation. The protocol was
IRB approved at all study sites as a prospective cohort and at UT Southwestern as the datacoordinating center. The etiologies of ALF included indeterminate ALF (N = 164), DI-ALF
(N = 131), and AI-ALF (N = 66). Each center determined whether a patient met criteria for
AIH except where reclassified by histology (see below).
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Primary end points were overall survival and spontaneous survival (SS), defined as survival
without transplantation or death, by 21 days. The criteria for transplantation varied by
center, however listing criteria are standardized. To be listed as Status 1 they had to meet
UNOS criteria for ALF, which are similar to study entry criteria, including presence in the
ICU, encephalopathy and a INR > 1.5. If a patient was not listed as Status 1, they were listed
at their native MELD score.
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The primary predictor was corticosteroid use, defined as any dose of prednisone PO or
methylprednisolone IV. In half of the cases, treatment had been begun prior to onset of ALF
while in the other half of cases the use of prednisone and related compounds began after the
diagnosis of ALF had been made. The AI-ALF group was used as the control group for the
corticosteroid benefit analyses. Sub-group analyses were performed using quartiles of AST,
ALT, MELD and grade of hepatic encephalopathy as measures of the degree of hepatic
inflammation and severity of illness. Infection was thought to be present when a positive
culture from blood, urine, tracheal aspirates, vascular catheters, wounds or ascites was
reported during study day 1-7. These data were initially analyzed based on the etiology of
ALF. A diagnosis of AIH was made by histology (when available) and ANA and antismooth muscle antibody, as determined by the principal investigator at each center. In
addition, for AI-ALF and indeterminate ALF patients, liver histopathology was reviewed
specifically to identify features of autoimmunity. The effects of corticosteroids were then
analyzed in a sensitivity analysis after group reassignment to AIH or indeterminate etiology
according to the overall impression of a single liver pathologist, as previously described.4
Hepatology. Author manuscript; available in PMC 2016 May 26.

Karkhanis et al.

Page 4

Author Manuscript
Author Manuscript

The reassignment to AIH was based upon 4 features of autoimmunity: distinctive patterns of
massive hepatic necrosis, presence of lymphoid follicles, plasma cell-enriched inflammatory
infiltrate and central perivenulitis. Eight patients initially considered to have AI-ALF by the
site PI were reclassified as indeterminate based upon absent features of autoimmunity, 2 of
whom received corticosteroids. Twenty-six patients initially considered to have
indeterminate ALF were found to have autoimmune features on histology and were
reclassified as AI-ALF, 4 of whom received corticosteroids. Therefore, after reclassification
according to histology, 84 patients were deemed to have AI-ALF (27 of whom received
corticosteroids) and 146 were deemed to have indeterminate ALF (19 of whom received
corticosteroids). The number of patients who received steroids and had a reclassified
diagnosis was very small (2 patients reclassified from AI-ALF to indeterminate and 4
patients reclassified from indeterminate to AI-ALF). Given the small N no statistically
significant differences were noted when overall survival or spontaneous survival was
calculated with the original diagnosis versus the reclassified diagnosis. Further subgroup
analyses were not done given the small N. As no differences were noted when the original
diagnosis was used versus the reclassified diagnosis in sensitivity analyses, all analyses
reported utilize the original diagnosis (66 with autoimmune [25 steroids, 41 no steroids], 164
with indeterminate [21 steroids, 143 no steroids], and 131 with drug-induced [16 steroids,
115 no steroids] ALF.
Corticosteroid Administration
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The decision whether to administer corticosteroids was entirely at the discretion of the site
PI, and was based upon an overall impression of an immune pathogenesis; however, the
specific criteria used by the site PI to administer corticosteroids were not available. The
timing, route of administration, and dosing of corticosteroids was also according to the site
PI, and were not uniform.
Statistical analysis
All data were analyzed for normality and were reported as mean [SD] or median [range], as
appropriate. The impact of steroid use on the primary endpoints of overall mortality and SS
were analyzed using a chi-square analysis. Because of the early time frame for death in ALF,
time to event analyses were felt to be inappropriate as an increase in survival time in a
twenty-one day period would not be clinically meaningful. Thus, sub-analyses were
performed using quartiles of AST, ALT, MELD and grade of hepatic encephalopathy as
measures of severity of illness (Quartile values listed in Supplemental Table 1). A sensitivity
analyses were performed after reclassifying the etiology of ALF based on histology.
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Additionally, univariate and multivariable logistic regression analyses were performed to
evaluate predictors of overall mortality and SS. All predictors with p<0.2 in univariate
analysis were evaluated in the multivariable model, and then sequentially removed to
establish the final model reported. Steroid use and diagnosis category were included in all
multivariable models as these were the central predictors evaluated. Diagnosis and coma
grade were evaluated as categorical predictors, and pH was analyzed as a dichotomous
variable around its median (7.4). In addition, the components of MELD (bilirubin, INR and
creatinine) were analyzed but not included in multivariable models along with the MELD
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score due to collinearity. Statistical analysis was performed using STATA 10.0 (College
Station, TX, USA) and SPSS 18 (IBM, USA). A p value of <0.05 was considered
statistically significant.

Results
Characteristics of Study Population
A total of 361 patients were studied, 18, 45, and 36% of whom were initially diagnosed with
AI-ALF, indeterminate ALF, and DI-ALF, respectively. Clinical characteristics of the 3
groups of patients are depicted in Table 1. Although baseline characteristics were generally
similar between groups, patients with AI-ALF tended to be older (p=0.001) and more likely
to be female (p=0.001) than those with DI-ALF or indeterminate ALF.
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Overall, 62 patients (17%) received some form of corticosteroid therapy (Table 1). Patients
with an initial diagnosis of AI-ALF had the highest rate of corticosteroid use (38%), higher
than those with indeterminate or DI-ALF (13% and 12%, respectively; p<0.001). There were
also statistically significant differences in several laboratory values between groups,
including AST, ALT, creatinine, and MELD score, all of which tended to be highest in the
indeterminate group (Table 1). The minority of patients had anti-nuclear (ANA), antimitochondrial (AMA) and anti-smooth muscle antibodies (ASMA) recorded. Among these,
ANA was significantly more likely to be positive in patients with AIH-ALF. There were no
significant differences in mean globulin levels between the groups.
Corticosteroid dose
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Complete data on dose and duration of corticosteroids administered was only available in a
proportion of patients (in 72% in AI-ALF, 50% of DI-ALF, and 62% of indeterminate
cases). The majority of patients received prednisone (8 AI-ALF, 7 DI-ALF, and 12
indeterminate ALF), The mean daily dose of prednisone in the 3 groups was similar (42.5
mg for AI-ALF, 41.6 mg for indeterminate ALF, and 42.3 mg for DI-ALF). Only a few
patients in each group received methylprednisolone (Solumedrol®) (5 AI-ALF, 2 DI-ALF
and 1 indeterminate ALF). Methylprednisolone doses were therefore converted to the
prednisone equivalents for analysis. Among those with known steroid doses, the mean
cumulative steroid dose (in prednisone equivalents) was 1287 ± 1144 mg. The median daily
dose (50 mg AI-ALF, 60 mg DI-ALF and 40 mg indeterminate-ALF) and median duration
of steroid therapy (24 days AI-ALF, 32.5 days DI-ALF and 31 days indeterminate ALF)
were similar between groups. The baseline characteristics of the patients who received
steroids versus those that did not were generally similar, though the average age of those
who received steroids was higher (Table 2). In addition, admission INR was lower in the
patients who received steroids than in the patients that did not receive steroids (2.64 vs. 3.78,
p=0.005).
Effects of corticosteroids on overall survival in ALF
Sixty-six percent (238 of 361 patients) survived, while 34% (123 patients) died, and 44%
(159 patients) received a liver transplant. Overall survival among all patients who received
corticosteroids was 61%, compared to 66% in those who did not receive corticosteroids
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(p=0.41; Figure 1). Similarly, corticosteroid administration had no apparent effect on overall
survival of patients with an initial diagnosis of AI-ALF (60% with steroids vs. 73% without
steroids; p=0.27). Thirty-four patients had liver histology available for analysis of features of
autoimmunity. After reclassification of these 34 patients according to histological criteria of
AI-ALF,4 overall survival was similar in patients who received corticosteroids compared to
those who did not (66% vs. 68%, respectively; p=0.53). In the subgroup of patients with DIALF, survival was 69% for those who received corticosteroids versus 66% for those who did
not (p= 0.82), and in patients with indeterminate ALF, survival was 57% for those who
received steroids versus 66% who did not (p=0.44). Similar results were obtained when the
data were analyzed after reclassification according to liver histopathology: overall survival
in patients with indeterminate ALF was 79% in those who received corticosteroids
compared to 66% who did not (p=0.20).
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Effects of corticosteroids on spontaneous survival in ALF
SS among patients who received corticosteroids (35%) was significantly higher than in
patients who did not receive corticosteroids (23%; p=0.047) (Figure 1). However, there were
no significantly differences in SS between steroid groups in any particular diagnosis
subgroup, including those with AI-ALF (32% v. 20%, respectively, p=0.25). In addition,
reassignment of etiology based upon a histological diagnosis of AI-ALF also yielded no
difference (26% in those who received corticosteroids and 21% in those who did not
(p=0.41).
Analysis of outcome according to severity of ALF

Author Manuscript

We hypothesized that the benefit of corticosteroids might be limited to patients with
relatively less severe ALF, and subsequently analyzed the effect of steroid administration on
overall and spontaneous survival according quartiles of AST, ALT and MELD. There were
no statistically significant differences in SS in patients who received corticosteroids among
all quartiles of ALT (Figure 2) or AST (data not shown). The highest 50% of ALT values
had improved spontaneous survival compared to those not receiving steroid therapy (54% vs
25%, respectively, p=0.003), and numerically higher overall survival (75% vs 61%,
respectively, p=0.20). (Figure 2)
Steroid administration did not result in any difference in overall survival or SS in patients
with MELD scores in the lowest three quartiles (Figure 3). In contrast, there was
significantly lower overall survival in patients who received steroids in the highest MELD
quartile (MELD > 40, 43%% v. 70%, respectively, p=0.03, Figure 3).

Author Manuscript

Subgroup analysis based upon encephalopathy stages 1-4 was also performed, and no
differences in outcome were observed in patients who received or did not receive
corticosteroids (data not shown).
Logistic Regression to Predict Mortality and Spontaneous Survival
Logistic regression was performed to identify independent predictors of overall mortality
and SS. Steroid use and diagnosis category were not predictive of overall mortality in uni- or
multivariable models (Table 3). In the final model to predict overall mortality, age (OR 1.37
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per 10 years), coma grade (OR 2.02 for stage 2, 2.65 for stage 3 and 5.29 for stage 4),
MELD (OR 1.07 per MELD point) and pH <7.4 (OR 3.09) were significantly predictive,
controlling for steroid treatment and diagnosis category. In addition, steroid use was
associated with diminished spontaneous survival (OR 1.80, p=0.049) in univariate analysis.
However, in the final model for SS, male gender (OR 1.58), the need for ventilator support
(OR 0.21), MELD (0.93) and ALT (1.02 per 100 U/L) were significantly predictive, while
steroid use (OR 1.8, p=0.12) and diagnosis category were not significant (Table 4). Though
the individual components of MELD were predictive of survival in some univariate and
multivariable analyses they did not perform as well as MELD and thus were not included in
the final multivariable models (Tables 3 and 4).
Effects of corticosteroids on the incidence of infection

Author Manuscript

Infection is a frequent complication of ALF, and the risk of increasing the incidence of
infection has been cited as a rationale to avoid corticosteroids in this patient population. The
overall rate of infection in patients was high but similar in those who received
corticosteroids (42%) and those who did not (40%; p=0.733). The rate of infection also did
not differ in subgroups according to etiology (Data not shown).

Discussion

Author Manuscript

In this prospectively collected, non-randomized study of large numbers of patients with ALF
we demonstrated that corticosteroids did not improve overall survival in AI-ALF, DI ALF, or
indeterminate ALF. In multivariable models, known predictors of poor outcomes in liver
failure including age, coma grade, MELD and pH<7.4 were the only significant predictors of
mortality, controlling for steroid use and diagnosis category. Interestingly, corticosteroid use
was significantly associated with lower overall survival in high MELD patients. Although
steroid use was marginally associated improved SS in univariate analysis, this difference did
not persist in multivariable analysis after controlling for important clinical predictors of
outcomes. In multivariable analysis controlling for steroid use and diagnosis category, the
need for mechanical ventilation and MELD were significantly associated with diminished
rates of SS, while ALT was significantly associated with increased SS. One potential
explanation for the lack of benefit of corticosteroids overall may be selection bias. Patients
in our study who received corticosteroids might have been more ill than those who did not,
which may have biased the results towards making corticosteroids appear less effective.
However, this is unlikely as the average MELD score in patients who received
corticosteroids was similar to those who did not, and INR was actually higher in the no
steroid group.
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Kings College criteria were not assessed as all required components were not available for
all patients. However it has previously been shown that MELD score has an excellent utility
in the prediction of outcomes in ALF, and correlates equally with Kings College Criteria17.
Subgroup analyses based on either MELD or degree of encephalopathy showed equivalent
results, suggesting that selection bias based upon disease severity was not the primary factor
responsible for our results.
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Based upon observations in patients with non-ALF autoimmune hepatitis 9, patients with AIALF would reasonably be expected to respond to corticosteroids. However, we did not
identify survival benefit in patients with AI-ALF who received corticosteroids, and noted a
non-significant trend towards decreased survival in this group. Although this observation
remained unchanged even after reclassification of etiology based on histology, it remains
possible that some patients were misclassified. Unfortunately, given the retrospective nature
of this study and lack of biopsy data in all patients, the “Revised Original Scoring System of
the International Autoimmune Hepatitis Group” was unable to be calculated. However, as
biopsy is not always possible in the acute setting in clinical practice, the diagnostic approach
utilized does reflect the “real world” experience at experienced liver centers in the US.
Overall, 38% of the total AI-ALF group were ANA negative. However, when the data for
this cohort was reviewed for the study by an independent pathologist and only those with a
histopathologically confirmed diagnosis of AIH were analyzed, steroids still showed no
benefit. This sensitivity analysis supports our conclusion.
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Another possible explanation for the lack of benefit of steroid treatment for AI-ALF patients
in this cohort is that AI-ALF may have a different pathogenesis than classical autoimmune
hepatitis, or that the condition of patients with AI-ALF is too advanced to allow for rescue
with corticosteroids. Indeed, patients with acute presentations of autoimmune hepatitis have
been shown to be less steroid responsive than patients with more chronic presentations, and
have significant biochemical and histologic differences.4,18,19 Specifically, patients with
acute presentations of AI-ALF more frequently have centrilobular necro-inflammatory
changes than those with classical AIH, a histological feature of severe, and treatmentrefractory AIH and acute cellular rejection in transplant recipients.4,20 Based on the present
study, patients with AI-ALF often have irreversible liver damage with or without treatment
with corticosteroids, and most will die without liver transplantation. Larger cohorts will be
required to determine whether these trends are clinically significant.
Despite the observation that administering corticosteroids was not associated with an overall
survival benefit, and potentially increased mortality in high MELD patients, there were no
statistically significant differences in the rate of infections in the patients that received
corticosteroids compared to the patients who did not. Previous studies have raised concern
that corticosteroids increased infectious complications in patients with ALF 8. Thus, the
explanation for the decreased survival in patients treated with corticosteroids is unclear.
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In our subgroup analysis of patients categorized by disease severity, only patients who
received corticosteroids and had ALT in the higher 50% of values had improved spontaneous
survival (54% steroid users vs 25% patients who did not receive steroids (p=0.003) and
modestly improved overall survival (75%), compared to those not receiving steroid therapy
(61%, p=0.2 Figure 2). We postulate that higher ALT may be a surrogate for an
inflammatory process that is more corticosteroid-sensitive than other mechanisms of injury.
Overall, our data suggest that patients with a higher ALT and lower MELD scores may
benefit from a liver biopsy since this group may be more likely to respond favorably to
steroid administration. In contrast, patients with lower ALT and higher MELD scores are
less likely to respond and will usually require OLT. In these cases liver biopsy does not seem
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warranted as intervention with steroids will not improve survival and may even be
detrimental. Our findings are similar to previous studies that have demonstrated that patients
with higher ALT values have an increased capacity to regenerate and, consequently, better
survival rates.21 In fact, cirrhotic livers have lower elevated liver enzymes, particularly in
cases of acute-on-chronic liver failure.22
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Finally, it has recently been shown that steroids in higher doses (prednisone 2-20 mg/kg/day
over 3-7days) in combination with UDCA might be useful in drug induced liver injury23,24.
In that study, patients that received steroids had a decrease in bilirubin and transaminases to
less than 50% of peak values in 2 weeks and normalized in 4-8 weeks. The greatest benefit
was in patients who had immune–mediated DILI. The number of patients in our study with
DI-ALF who received both steroids and ursodiol is too small to perform any meaningful
analyses. However, it is possible that the steroid dose and/or duration in this study was not
sufficiently large or standardized to see maximal effects, or that steroids could be of greater
benefit if used in combination with ursodiol or other agents, and additional studies are
warranted in the future.
One major limitation of our study was that analyses were conducted retrospectively and the
use of steroids was neither randomized nor standardized. Consequently, the administration
of corticosteroids was not uniform in either in formulation, dose, route of administration,
and duration of treatment. The use and duration of steroids was completely at the discretion
of the provider and this alone could bias or confound our results. However, our findings
across almost all subgroups suggest there is no survival benefit with steroid use, even in the
AI-ALF group, in whom immunosuppression protocols with corticosteroids may be more
likely to be standardized.
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In conclusion, this prospectively collected large multicenter cohort study demonstrates no
survival benefit with the administration of corticosteroids for patients with ALF of presumed
autoimmune or drug induced etiology. Further investigation, if possible, should include a
prospective, randomized study of the safety and efficacy of corticosteroids in patients with
AI- and DI-ALF. In the interim, based upon the data presented, the risks and benefits of
corticosteroid administration should be carefully weighed and early discontinuation
considered in the absence of a clear salutary effect, especially in high MELD patients.
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ALF

Acute liver failure

DI

Drug-induced

AI

Autoimmune

SS

Spontaneous survival

ANA

Anti-nuclear antibodies

AMA

Anti-mitochondrial antibodies

ASMA

Anti-smooth muscle antibody

MELD

Model for End Stage Liver Disease
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Figure 1.

Overall and Spontaneous Survival among different etiologies of ALF
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Figure 2.

Overall and Spontaneous Survival among Quartiles of ALT
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Figure 3.

Overall and Spontaneous Survival among Quartiles of MELD
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Table 1

Author Manuscript

Baseline demographics by diagnosis group.
Variable

AI-ALF N=66

DI-ALF N=131

Indeterminate N=164

P-value

Male

11 (17)

40 (31)

70 (43)

0.001

Female

55 (83)

91 (69)

94 (57)

Age, Mean (SD)

46 (16)

44 (14)

39 (15)

White

37 (56)

91 (69)

118 (72)

African American

Gender (%)

0.001

Race (%)

Author Manuscript

18 (27)

21 (16)

25 (15)

Asian

5 (8)

10 (8)

10 (6)

Native American

0 (0)

5 (4)

4 (2)

Other

6 (9)

5 (4)

7 (4)

Non-Hispanic

52 (79)

112 (86)

146 (89)

Hispanic

14 (21)

18 (14)

18 (11)

Mean MELD (SD)

30.9 (9.5)

32.8 (8.8)

34.5 (9.5)

0.03

AST (U/L)

619 (560)

1190 (1997)

2193 (3640)

<0.001

ALT (U/L)

601 (510)

1227 (1799)

1696 (2235)

<0.001

Total Bilirubin (mg/dL)

23.2 (9.1)

20.9 (11.4)

21.0 (12.7)

0.37

Creatinine (mg/dL)

1.5 (1.4)

2.0 (1.8)

2.2 (1.8)

0.02

3.33 (3.17)

3.44 (2.37)

3.76 (3.12)

0.48

0.20

Ethnicity (%)
0.13

Laboratory values, mean (SD)

Author Manuscript

INR
Positive autoimmune serologies (%)*
ASMA

15/24 (63)

8/20 (40)

11/30 (37)

0.14

ANA

39/41 (95)

25/34 (74)

32/39 (82)

0.03

AMA

1/7 (14)

1/12 (8)

1/13 (8)

0.88

3.85 (1.72)

2.99 (1.41)

3.38 (6.8)

.56

1

20 (30)

42 (32)

36 (22)

2

24 (36)

41 (31)

46 (28)

3

13 (20)

26 (20)

38 (49)

4

9 (14)

22 (17)

44 (27)

Ventilatory Support (%)

28 (42)

63 (39)

103 (63)

Steroid Use (%)

25 (38)

16 (12)

21 (13)

25

16

21

Globulin, mean (SD)
Coma grade (%)

Author Manuscript

Total number of subjects
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Variable

Author Manuscript

AI-ALF N=66

DI-ALF N=131

Indeterminate N=164

Daily Prednisone Dose**, Median (IQR)

50 (30-61.3)

60 (40-62)

40 (23-50)

Days of Prednisone, Median (IQR)

24 (6.3-57.5)

32.5 (24.3-36.3)

31 (17.3-73)

P-value

*

Autoimmune serologies were evaluated in the minority of patients (as indicated) and were considered positive with a titer of ≥ 1:40.

**

Complete data on prednisone or prednisone equivalent dose was available in 12/25 AI-ALF cases, 7/16 DI-ALF cases and 8/21 indeterminate
cases.
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Table 2

Author Manuscript

Baseline characteristics by steroid use.
Variable

Steroid (n=62)

No steroid (n=299)

P-value

0.72

Gender (%)
Male

22 (35)

99 (33)

Female

40 (65)

200 (67)

Age, mean (SD)

46 (15)

41 (15)

0.02

White

45 (73)

201 (67)

0.68

African American

Race-N(%)

Author Manuscript

10 (16)

54 (18)

Asian

2 (3)

23 (8)

Native American

1 (2)

3 (1)

Other

4 (6)

18 (6)

Non-Hispanic

55 (89)

255 (86)

Hispanic

7 (11)

43 (14)

MELD, mean (SD)

31.9 (9.9)

33.5 (9.2)

0.24

AST (U/L)

1007 (2459)

1653 (2871)

0.10

ALT (U/L)

897 (1375)

1414 (1990)

0.06

Total Bilirubin (mg/dL)

22.4 (12.6)

21.2 (11.5)

0.44

2.1 (1.8)

2.0 (1.7)

0.53

INR

2.64 (1.3)

3.76 (3.08)

0.005

pH

7.43 (0.07)

7.37 (0.62)

0.51

ASMA

11/21 (52)

23/53 (43)

0.48

ANA

18/20 (90)

78/94 (8.3)

0.43

AMA

2/7 (29)

1/25 (4)

0.05

1

22 (35)

76 (25)

0.41

2

18 (29)

93 (31)

3

12 (19)

65 (22)

4

10 (16)

65 (22)

28 (45)

166 (56)

Ethnicity (%)
0.52

Laboratory values, mean (SD)

Creatinine (mg/dL)

Author Manuscript

Autoimmune serologies, positive (%)*

Coma grade (%)

Author Manuscript

Ventilatory Support (%)

0.14

*

Autoimmune serologies were evaluated in the minority of patients (as indicated) and were considered positive with a titer of ≥ 1:40.
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Table 3

Author Manuscript

Uni- and multivariable analysis to predict overall mortality.
Univariate

Multivariate

Variable

OR

p-value

OR

p-value

Steroid treatment

1.27

0.72

1.56

0.19

AI-ALF

--

--

--

--

DI-ALF

1.10

0.78

1.22

0.59

Indeterminate

1.17

0.51

1.00

1.00

Age (per 10 years)

1.37

<0.001

1.39

<0.001

1

--

--

--

--

2

2.02

0.03

1.74

0.12

3

2.65

0.006

2.37

0.02

4

5.29

<0.001

5.18

<0.001

Ventilatory Support

3.11

<0.001

--

--

MELD

1.07

<0.001

1.05

0.001

Creatinine (mg/dL)

1.29

<0.001

--

--

pH<7.4

3.09

<0.001

2.68

0.002

Diagnosis

Author Manuscript

Coma grade

*

Additional variables tested and not significant with a p<0.2 include: gender, AST, ALT, bilirubin, INR.
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Table 4

Author Manuscript

Uni- and multivariable analysis to predict spontaneous survival.
Univariate

Multivariate

Variable

OR

p-value

OR

p-value

Steroid treatment

1.80

0.049

1.80

0.12

AI-ALF

--

--

--

--

DI-ALF

1.18

0.63

1.49

0.33

Indeterminate

1.00

0.98

1.36

0.46

1.58

0.07

--

--

1

--

--

--

--

2

0.56

0.05

3

0.50

0.04

4

0.22

<0.001

Ventilatory Support

0.24

<0.001

0.21

<0.001

MELD

0.93

<0.001

0.93

<0.001

INR

0.84

0.01

--

--

ALT (per 100 U/L)

1.02

<0.001

1.04

<0.001

AST (per 100 U/L)

1.01

0.004

--

--

Bilirubin

0.93

<0.001

--

--

pH<7.4

0.60

0.13

--

--

Diagnosis

Male gender

Author Manuscript

Coma grade

Author Manuscript

*

Additional variables tested and not significant with a p<0.2 include: age, creatinine.
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